Virus Peptides TRIZ Cases
- Variant AAV Capsids for Retina and Trabecular Meshwork Transduction
Targeted VP1 capsid mutations improve AAV delivery to the retina and trabecular meshwork, raising ocular transduction efficiency.
- Oncolytic Virus Expressing GM-CSF for Tumor-Targeted Immune Activation
Tumor-targeted expression of GM-CSF and co-stimulatory molecules boosts anti-tumor immunity while reducing systemic off-target toxicity.
- Helper Plasmid Architecture for Higher Recombinant AAV Yield
A helper plasmid using DA′ or AD′ sequences with Rep/Cap and a P5 promoter raises recombinant AAV yield for lower-cost gene therapy production.
- Engineered AAV Capsids for Human Pancreatic Islet Transduction
Directed-evolution AAV capsid variants improve pancreatic islet tropism and transduction, reducing vector dose while sustaining protein expression.
- AAV Capsid Tropism Redirection via Cell-Type-Specific RNA Screening
Cell-type-specific promoters enable RNA-driven AAV capsid screening in non-transgenic animals to improve CNS transduction and targeting.
- Fusogenic Oncolytic Virus Platform for Stronger Anti-Tumor Immunity
Fusogenic proteins and immune stimulators are combined in one oncolytic virus to improve tumor killing, antigen release, and immune response.
- Engineered rAAV Capsids for Brain Enrichment and Lower Liver Uptake
Capsid peptide insertions and substitutions shift rAAV tropism toward the brain and away from the liver, lowering immune response risk.
- CHO Cell ERV Gag Editing to Reduce Retroviral Particle Release
CRISPR-Cas9 gag disruption in CHO endogenous retroviruses cuts retroviral-like particle release while preserving biopharmaceutical production.
- Mutant AAV9 Microdystrophin Vector for Lower-Dose DMD Gene Delivery
Mutant AAV9 capsids and a CBA-Kozak microdystrophin cassette improve DMD gene delivery at lower doses, reducing immune response and toxicity.
- Adenoviral VLP Vaccines With Inactive HERV Immune-Suppressive Domains
Mutated HERV immune-suppressive domains let adenoviral VLP vaccines retain antigen presentation while triggering strong antibody and T-cell responses.
- Modified Oncolytic Viruses for Tumor Antigen Release
Fusogenic proteins and immune-stimulatory genes help release tumor antigens and strengthen anti-tumor responses during checkpoint blockade.